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The interpretation of pulmonary function tests (PFTs) to diagnose respiratory diseases is built 
on expert opinion which relies on the recognition of patterns and clinical context for the 
detection of specific diseases. In the study, we aimed to explore the accuracy and inter-rater 
variability of pulmonologists when interpreting PFTs and compared it against that of artificial 
intelligence (AI)-based software which was developed and validated in more than 1500 
historical patient cases. 
120 pulmonologists from 16 European hospitals evaluated 50 cases comprising with PFT and 
clinical information resulting in 6000 independent interpretations. AI software examined the 
same data. ATS/ERS guidelines were used as the gold standard for PFT pattern 
interpretation. The gold standard for diagnosis was derived from clinical history, PFT and all 
additional tests.  
The pattern recognition of PFTs by pulmonologists (senior 73%, junior 27%) matched the 
guidelines in 74.4% (±5.9) of the cases (range: 56-88%). The inter-rater variability of 0.67 
(kappa) pointed to a common agreement. Pulmonologists made correct diagnoses in 44.6% 
(±8.7) of the cases (range: 24-62%) with a large inter-rater variability (kappa= 0.35). The AI-
based software perfectly matched the PFT pattern interpretations (100%) and assigned a 
correct diagnosis in 82% of all cases (p<0.0001 for both measures). 
The interpretation of PFTs by pulmonologists leads to marked variations and errors. AI-based 
software provides more accurate interpretations and may serve as a powerful decision support 
tool to improve clinical practice. 
 
INTRODUCTION 
Pulmonary function testing (PFT) is our primary tool to evaluate the function of the 
respiratory system.[1] In practice, the interpretation is based on expert opinion and involves 
the recognition of a pattern (obstructive, restrictive, mixed, and normal) and the grading of its 
severity according to international guidelines.[2-4] To arrive at the final diagnosis the results 
of PFTs are combined with patient information, symptoms and possibly, the results of other 
tests, such as imaging, blood analysis, biopsies, and exercise tests.[5, 6]  
In 2005, an American Thoracic Society/European Respiratory Society (ATS/ERS) task force 
designed a simplified algorithm to assess lung function in clinical practice.[2] However, 
when these recommended guidelines were translated into software for diagnostic decision 
support, it led to only 38% of correct disease predictions. Adding patient characteristics into 
such an algorithm improved the accuracy to 68%, highlighting a vast potential for automated 
diagnostic labelling when combining PFTs with clinical information.[7] In fact, the Belgian 
pulmonary function study (BPFS) demonstrated that experts panels could reach 77% 
accuracy when predicting the diagnosis based on PFTs and clinical history alone.[8] 
Although one may doubt if a computer algorithm carries any added value to a group of 
experts, the question if it may help individual readers is yet to be answered. 
The number of successful applications of artificial intelligence (AI) is quickly rising. 
Supported by a number of outstanding achievements in the field and because of its unlimited 
potential to deal with big data, high expectations are also emerging for healthcare. For 
instance, one study demonstrated the ability of an AI algorithm to identify and classify skin 
cancer with similar expertise as 21 board-certified dermatologists.[9] Another study reached 
the same performance when analysing retinal fundus images for the identification of diabetic 
retinopathy.[10] Moreover, there are multiple examples from radiology in detecting traces of 
breast and lung cancer.[11, 12] Notwithstanding these technical superiorities of AI-based 
systems, translation into clinical practice with broad acceptance has been very 
challenging.[13-15] Since PFTs are entirely standardised and used worldwide[16], they are 
ideally suited for the development of AI algorithms for test interpretation and diagnostics. 
PFTs provide an extensive series of numeric outputs, easily controllable by the computers, 
yet its patterns are not always easily perceptible or appropriately recognised by the human 
eye. Moreover, the example of automated interpretation for electrocardiograms which is 
widely adopted and standardised in most equipment highlights its potential use. 
In this study, we hypothesise that AI can improve the clinical reading of PFTs and overcome 
the variable test interpretation of individual pulmonologists. We explored the accuracy and 
inter-rater variability of pulmonologists when interpreting patterns of PFTs and when 
suggesting a specific category of respiratory disease diagnosis based on limited clinical 
information and PFTs. Secondly, we compared the pulmonologists’ performance with that of 




In this multicentre non-interventional study, 120 pulmonologists from 16 hospitals in 5 
European countries participated. They independently evaluated complete PFTs (pre-and/or 
post-bronchodilator spirometry, whole-body plethysmography for lung volumes and airway 
resistance, and diffusing capacity) and limited clinical information (smoking history, cough, 
sputum and dyspnoea) of 50 randomly selected patients, admitted to the University Hospital 
of Leuven (Belgium) for a respiratory problem. Evaluation sessions were performed in each 
hospital in the period from August 15th, 2017 till December 13th, 2017. All pulmonologists 
independently examined different patient cases according to a pre-established protocol by 
providing: A/ PFT pattern interpretation: obstructive, restrictive, mixed or normal pattern, B/ 
choice of one preferred diagnostic category: 1/asthma, 2/chronic obstructive pulmonary 
disease (COPD), 3/other obstructive diseases (OBD, including bronchiectasis, bronchiolitis 
and cystic fibrosis), 4/interstitial lung disease (including idiopathic pulmonary fibrosis, 
nonspecific interstitial pneumonitis and sarcoidosis), 5/pulmonary vascular disease (including 
pulmonary hypertension, embolism and vasculitis), 6/neuromuscular disease (including 
paralysis of the diaphragm, poliomyelitis, myopathy), 7/thoracic deformity (including 
pneumectomy, lobectomy, chest wall problems, kyphoscoliosis), 8/healthy and 9/other 
diseases. C/ confidence in their decision on a Likert scale: from 1 point (“absolutely not 
sure”) till 5 points (“absolutely sure”). An example is shown in the supplementary material; 
S1 – S2. D/ Finally, the same patient files were examined by an in-house developed AI-based 
software for PFT interpretation and diagnostic suggestion. 
Study Population 
The study included a random sample of 50 subjects prospectively collected at the outpatient 
clinic in August 2017. All enrolled subjects were Caucasians older than 18 years who had 
performed a complete PFT and provided clinical information. The gold standard diagnosis 
was derived from clinical history, PFT, and all necessary additional tests, and finally 
confirmed by an expert panel in Leuven. This ad-hoc expert panel consisted of 3 experienced 
clinicians that reviewed all baseline and clinical follow-up data to agree on a final gold 
standard diagnosis out of the 9 categories. Consensus was reached for all these cases. 
Baseline characteristics are shown in Table 1, covering a wide range of respiratory diseases 
that may present with an abnormal PFT. Other conditions (such as lung cancer, 
cardiovascular disease, ear-nose-throat problem) were excluded from the test sample (n=3). 
The Ethics Committee of the University Hospital in Leuven approved study protocol (study 
number S60619, approved on August 4th, 2017). The study design can be found on 
www.clinicaltrials.gov (NCT03264417). All included patients provided informed consent for 
the use of their data (S60243, approved on June 23rd, 2017). 
AI Software 
The development of software for automated reading of PFTs was performed in R language 
and its machine learning framework. The software used as input the same lung function data 
as presented to the pulmonologists (absolute values, percent predicted of normal reference 
values and z-scores, also shown in S1) combined with the patient characteristics age, pack-
years, sex, and body mass index (BMI). For pattern interpretations, the PFT algorithm was in 
line with ATS/ERS strategies.[2] However, the engine for complex diagnostic categorisation 
had to be developed, and a machine learning approach was adopted.  
The machine learning model was built using data from 1430 subjects used in our previous 
work to ensure a broad variety of data.[7, 8, 17] This data came from two cohorts: 1/ 
BPFS[8], a prospective cohort study that enrolled a clinical population-based sample (n=851) 
of all successive undiagnosed patients admitted for the first time to one of the 33 participating 
Belgian hospitals due to respiratory symptoms; 2/a retrospectively collected PFT data cohort 
of patients followed at the outpatient clinic of the University Hospital of Leuven based on 
predefined established diagnoses (neuromuscular disease (n=112), chest-pleural wall 
problems, including pneumectomy and lobectomy (n=64), pulmonary vascular disease 
(n=76), other obstructive diseases (n=100), COPD (n=47), asthma(n=40), healthy (n=50), 
interstitial lung disease (n=90)). Briefly, all subjects were Caucasians between 18 and 85 
years old who had performed a complete PFT (including post-bronchodilator spirometry, 
whole-body plethysmography for lung volumes and airway resistance, and diffusing 
capacity). The final diagnosis was established with all additional tests deemed necessary by 
the responsible clinician, the patients’ history, and PFTs. Subsequently, it was validated by an 
ad-hoc installed expert panel (BPFS) or by the clinical expert panel taking care of the patients 
in follow-up (Leuven data). The expert discussion of the BPFS were organized during the 
local meetings of physicians, at which all individual cases were presented to obtain a final 
diagnosis by consensus. In case there was disagreement, voting was used for a final gold 
standard diagnosis and if needed, a secondary diagnosis [8]. For the retrospective PFT data 
collection of patients followed at the University Hospital of Leuven, corresponding medical 
records were verified on the final diagnosis. For the few cases in which there was doubt on 
the diagnosis, the PFT data were not extracted and these cases were rejected. Internal 10-fold 
cross-validation tuned the machine learning model with the best model resulting in the 
diagnostic accuracy of 74%. To obtain an unbiased estimate of accuracy and validate 
findings, the model was run at the Leuven pulmonary service on a randomly selected sample 
of 136 subjects. The model demonstrated a consistent diagnostic accuracy of 76%.[17] 
Probabilistic output for each of the diagnostic categories obtained by the machine learning 
model is summarised in the report (Supplement S3). 
Pulmonary Function Tests 
All PFTs were performed with standardised equipment by respiratory technicians (Masterlab, 
Würzburg, Germany), according to the ATS/ ERS criteria.[18] Spirometry data, as well as 
plethysmography and single-breath diffusing capacity data, were given as absolute values, 
but also expressed as percent predicted of normal reference values and as Z-scores.[19-21] In 
the current prospective study, these data were presented to the AI software and 
pulmonologist, the latter having also access to the corresponding flow-volume loops, 
plethysmography and diffusing capacity manoeuvers. 
Statistical analysis 
Statistical analysis was performed using R software version 3.3.3. (Vienna, Austria: R 
Foundation for Statistical Computing; 2017). Figures were produced using GraphPad Prism 
version 6 (GraphPad Software, La Jolla USA). The inter-observer agreements were assessed 
using Fleiss' Kappa for multiple raters on categorical data. Interpretative strategies for lung 
function tests from ATS/ERS task force were used as the gold standard to define a correct 
lung function pattern.[2] Preferred diagnostic category, by pulmonologists or software, was 
considered as correct if it corresponded to the gold standard diagnosis made historically by 
the expert panel based on all data. For both measures, PFT pattern interpretation and 
diagnostic category suggestion, accuracy was defined as the percentage of correctly labelled 
cases. The T-test and Mann-Whitney U test were used to evaluate differences between groups 
with normal and nonparametric distribution, respectively. The Kruskal-Wallis test was used 
to determine statistical difference between multiple groups. One-sample T-test was used to 
assess the difference of AI performance and the average accuracy of pulmonologists. 
 
RESULTS 
There were 120 pulmonologists who all together made 6000 evaluations of PFTs with clinical 
information. The pulmonologist group consisted of more senior level members (n=88, 
established pulmonologists) than junior members (n=32, pulmonologists in training). A 
minimal number of five pulmonologists per centre was needed to participate. 
A/ PFT pattern interpretations 
Applying the ATS/ERS interpretative strategies for PFTs revealed that the population 
consisted of 18 patients with obstructive, 10 with restrictive and 22 with normal lung function 
pattern, while there were no subjects with a mixed pattern. The interpretations of 118 
pulmonologists (data were missing from 2) matched with the reference PFT pattern in 74.4 
(±5.9)% of the 50 cases, ranging from 56% to 88% per individual. The identification of a 
restrictive pattern was more difficult (positive predictive value (PPV)= 59% and sensitivity= 
75%) as compared to normal and obstructive patterns (Table 2). Even though a mixed pattern 
was not present, 376 (=6%) cases were interpreted as mixed. A Kappa of 0.67 signified a 
considerable inter-rater variability or disagreement between different pulmonologists. When 
the accuracy between different centres was compared, no significant differences in correct 
detections were found (p=0.06) (Figure 1A). There were no significant differences between 
university and non-university centres (p=0.06) or between senior and junior readers (p=0.49). 
Interestingly, out of the 285 misclassified normal patterns falsely labelled into an obstructive 
pattern, 216 (=76%) were on the 4 cases having a FEV1/FVC ratio above lower limits of 
normal but still below 0.7 fixed cut-off.  
B/ Preferred diagnostic categories 
For an individual pulmonologist, it was rather difficult to assign a correct preferred diagnostic 
category based on complete PFT data and clinical information. The mean accuracy of 6000 
evaluations was only 44.6 (±8.7)%, and it ranged from 39% to 51% per centre and from 24% 
to 62% per individual pulmonologist (Figure 1B). A low kappa score of 0.35 was indicative 
of a common disagreement between pulmonologists. Interestingly, age or clinical experience 
of the examiners did not influence the mean accuracy (Seniors= 45 (±4.2)% vs Juniors= 43.6 
(±4.8)%, p=0.46). Likewise, results were neither different between the hospitals (p=0.44), nor 
affected by hospital type (university= 44.1 (±9.4)% vs non-university= 45.2 (±7.8)%, p=0.47) 
or by country (p=0.26).  
Due to a higher sensitivity, patterns of healthy subjects (true positive rate= 71%) and subjects 
with COPD (true positive rate= 65%) were more often identified on lung function than any of 
the other categories. Patient cases of less prevalent conditions, without a straightforward 
pattern (“fingerprint”) on lung function, were more difficult for the pulmonologists (thoracic 
deformity and neuromuscular disease, true positive rate= 25%) (asthma, true positive rate= 
20%). Detailed statistical group comparison is shown in Table 3 and Figure S4. 
C/ Confidence in decision-making 
Rarely, pulmonologists were “absolutely not sure” (in 2.7% of cases) or “not sure” (11.5%) 
when suggesting the preferred diagnostic category. Most commonly they were “sure” 
(36.5%) and “absolutely sure” (16%) in their decisions. Higher confidence in diagnostic 
suggestion was observed in decisions that were correct (p<0.0001) as compared to the 
incorrect decisions. However, high confidence did not necessarily lead to correct diagnosis. 
From all “sure” and “absolutely sure” records, only 51.8% of the diagnosis were correct 
(Data in supplement S5 – S6). 
D/ Comparison with the AI software 
The in-house developed AI-based software perfectly matched the pattern interpretations of 
ATS/ERS guidelines (100%). Software response was 0.2 seconds, giving immediate and 
consistent interpretations. Moreover, it assigned a correct diagnostic category in 82% of the 
cases, which was highly superior to the average 44.6% accuracy of the pulmonologists (p 
<0.0001) (Figure 2). It also proved to be highly sensitive in recognising COPD, 
neuromuscular disease, interstitial lung disease and healthy subjects. Concerning PPV, the 
software showed powerful results for the majority of the respiratory disease diagnoses 
(details in Figure 3 and Table 4). Both sensitivity and positive predictive value of the AI-
based algorithm were superior to expert-based diagnostic category allocation in each of the 
eight disease groups (Figure 3). AI lacked sensitivity for the OBD group, which was 
recouped by the very high PPV.  
DISCUSSION 
In this study, we explored the accuracy and the consistency between pulmonologists when 
interpreting PFT patterns and providing a preferred diagnostic category. PFT pattern 
interpretations matched the ATS/ERS guidelines in 74.4% of the cases with an inter-rater 
variability of 0.67, demonstrating that such a fundamental task is prone to mistakes and 
disagreements. PFTs combined with limited clinical information were difficult for 
pulmonologists as the only tool for reaching an accurate diagnostic category (accuracy of 
44.6% and significant variability of kappa 0.35). However, our advanced AI-based software 
for the automated clinical reading of PFTs, perfectly interpreted (100%) PFT patterns and 
pointed to the correct diagnostic category in 82% of all cases. Consequently, it outperformed 
the pulmonologists in both tasks by 34% and 84% respectively, which demonstrates that 
individual pulmonologists do not sufficiently capture the information available in PFTs. 
Facilitating clinical practice with decision support systems is not a new idea, and it has been 
shown that a majority (64%) of such systems do improve performances of individual 
clinicians.[22] Nowadays, we regularly use them to interpret electrocardiograms, to analyse 
mammogram irregularities or as reminders for drug prescription.[23, 24] Although automated 
analysis of PFTs had been evaluated before[25, 26], none has become a clinical reality. First, 
there is an obvious difficulty in reaching a preferred diagnosis without knowing the clinical 
context.[27, 28] Second, there is a lack of clear international diagnostic guidelines to label 
respiratory diseases based on PFTs with controversial and often arbitrary choice of cut-offs to 
label abnormality. It implies that not all pulmonologists are using the same interpretative 
strategies in their daily routine.[29, 30] For example, a typical conflict is often seen in the 
first interpretative step: should we take the lower limits of normal or fixed 0.7 cut-off for 
FEV1/FVC ratio.[31] Undoubtedly, it will explain some of the differences between the 
interpretations of pulmonologists, but it also highlights a more general concern. Different 
recommendations on which cut-offs to use will reclassify individual patients from healthy to 
diseased and vice versa, while in real life disease processes will present as a continuum 
around prefixed values. The strength of complete PFTs lies in the variety and multitude of 
tests in order to recognise disease-specific patterns, regardless of these fixed cut-off points.  
Using the AI, we approached each disease as having a unique fingerprint on the PFT. As 
such, AI identifies subtle and defining characteristics that are challenging for humans to 
detect and incorporates them into a powerful discriminating diagnostic algorithm. In our case, 
AI takes complete input data and maps them into a high dimensional space. As a result of a 
large number of known disease cases, with known magnitudes and patterns between all input 
data, AI will construct most optimal hyperplanes which categorise new examples. Once 
presented with the data of a new patient, AI maps them into the same high dimensional space 
and predict to which category it belongs. Such a multi-dimensional approach exceeds human 
capabilities to observe the same data in terms of accuracy. Fundamentally, AI algorithm is 
not anymore dependent on the arbitrary cut-offs but a purely patient-data-driven knowledge 
system. In fact, with the increase in computing resources, modern AI algorithms have entirely 
moved away from rule-based systems and currently adopt a probabilistic approach. Our study 
confirms that a unique data-driven fingerprint of each disease often exists in the PFTs. 
A fascinating characteristic of an AI-based software is its ability to improve over time by 
getting exposure to new and more difficult cases. In other words, the developed software may 
improve - as physicians do - by learning from mistakes and gaining experience. It is too 
ambitious to expect the software to be correct in 100% of the cases, as some respiratory 
diseases do not show characteristic lung function abnormalities. Particularly for early disease 
stages or combined complex disease processes, disease-specific characteristics may be 
hidden. As the current accuracy of the AI software is situated within the range of what 
clinical expert panels reached during the Belgian pulmonary lung function study[8], there is 
probably little room for improvement. However, it also indicates that a computer can process 
all necessary information as effectively as a group of experts - not the individual - yet at a 
much higher speed and with hundred percent consistency for the same data input. The further 
usefulness of the AI software will be demonstrated if it decreases the time to final diagnosis, 
reduces the number of tests needed for a final diagnosis, and if by standardizing PFT 
interpretation, a number of misdiagnoses can be avoided.  
Comparable with the human examiner marking his confidence on the Likert scale, AI 
expresses its certainty as a probability for a patient to belong to one of the disease categories. 
In the situations where AI made a wrong diagnostic suggestion, it should be mentioned that it 
never attributed a high probability to this diagnosis. More specifically, probability barely 
crossed 50% in two out of the nine mislabels and it was lower than 50% in the seven other 
cases.  Surprisingly, the use of the COPD assessment test (CAT) for the quantification of 
symptoms in the BPFS study, did not contribute to further improving the accuracy of our AI 
software. It suggests that most respiratory diseases present with similar non-specific 
symptoms such as cough and dyspnoea. It is tempting to speculate that more input, such as 
more extensive history taking, and tests like exhaled nitric oxide, forced oscillometry and/or 
blood/radiological markers, could enhance its future potential. In particular, for diseases such 
as asthma which can perfectly present with a normal PFT, the added value of such tests when 
integrated into our AI-based software, is obvious.  
A limitation of the current study is that we underestimated the accuracy of the pulmonologists 
by limiting the amount of clinical data to suggest a preferred diagnosis. In reality, a diagnosis 
is reached by a synergy of multiple factors, including expanded history, clinical examination, 
imaging and blood sampling. The real-life situation may therefore yield better outcomes. 
Additionally, the test sample we used may not entirely reflect the prevalence of diseases that 
pulmonologists confront in daily clinical practice. It is clear that we only explored the 
maximum output that could be reached from PFTs and clinical information, representative of 
the first diagnostic encounter. Furthermore, we did not formally test the level of agreement 
within the ad-hoc expert panel to define the final diagnosis. Although the experts relied on all 
available test information, one may speculate that providing the AI interpretation would have 
favoured their initial agreement. A final limitation is that the risk of misinterpretation and 
misdiagnosis increases if tests are poorly performed.[32] However, sufficient quality of the 
tests is needed for both human and computer interpretations. 
To conclude, our data indicates that interpretation of PFTs and the suggestion of primary 
respiratory disease diagnosis by pulmonologists is highly variable. The AI-based software has 
superior performance and may provide a powerful decision support tool for clinicians. The 
significance of such technology in improving clinical practice will drive real-life acceptance 
of the medical community. 
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Figure 1: Comparison of correct detections per each centre. Panel A/ PFT pattern 
interpretation. No significant difference between centres (p=0.06). Panel B/ Preferred 
diagnostic category. No significant difference between centres (p=0.44). Data anonymised. 
Data presented: line at the median (IQR), + at the mean, range. 
Figure 2: Comparison of results obtained by pulmonologists (red bars) versus results 
achieved by AI- software (green bars). Correct detections are significantly (p<0.0001) higher 
for AI-software (improvement of 34% for PFT pattern interpretation and 84% for diagnostic 
category detection). 
Figure 3: Performance of pulmonologists in comparison with the AI software for each 
disease category. Left bars are values obtained when software analysed study population; 
right bars are values obtained by pulmonologists’ evaluation. Panel A/ Sensitivity (=True 
positive / (True positive + False Negative) shows how many relevant subjects (from a 
specific group) were correctly identified. Panel B/ Positive predictive value (=True positive / 
(True positive + False Positive) shows how many labelled subjects rightly belonged to the 
specific group. COPD = Chronic Obstructive Pulmonary Disease, ILD = Interstitial Lung 
Disease, NMD = Neuromuscular Disease, OBD = Other Obstructive Diseases, PVD = 





















Table 1: Population characteristics of the 50 subjects whose lung function was evaluated in the study 
 Asthma COPD OBD NMD TD ILD PVD Healthy 
Subjects, n 8 11 4 3 5 10 4 5 
Sex, M/F 5/3 8/3 3/1 2/1 4/1 6/4 3/1 3/2 
Age, years 57 (27 - 70) 64 (38 - 77) 53 (34 - 77) 65 (48 - 72) 60 (52 - 68) 70 (51 - 83) 80 (62 - 81) 64 (38 – 74) 
FEV1, z-score. -0.57 (-2.70 to 0.73) -1.41 (-3.95 to 0.41) -2.97 (-4.05 to -1.39) -2.47 (-2.87 to -1.97) -2.76 (-2.94 to -1.77) -0.65 (-2.74 to 1.01) 0.17 (-2.23 to 0.78) 0.24 (-0.01 to 1.63) 
FVC, z-score -0.41 (-1.86 to 2.00) 0.70 (-2.48 to 2.07) -2.51 (-4.37 to -0.48) -2.58 (-2.85 to -1.93) -2.68 (-2.79 to -2.30) -0.97 (-3.42 to 0.79) 0.66 (-1.83 to 1.59) 0.11 (-0.06 to 1.22) 
FEV1/FVC, z-score -1.01 (-2.79 to 0.29) -2.54 (-4.86 to -1.54) -2.51 (-4.37 to -0.48) -0.41 (-0.60 to 0.07) -0.83 (-1.41 to 1.47) 0.85 (-0.25 to 2.05) -0.90 (-1.10 to -0.53) 0.32 (-0.26 to 0.50) 
TLC, z-score 0.01 (-1.04 to 2.39) 1.55 (-1.49 to 2.80) 0.17 (-0.74 to 1.20) -2.23 (-3.01 to -2.17) -2.98 (-5.05 to -1.10) -2.54 (-4.96 to -1.00) -0.29 (-1.53 to 0.11) -0.13 (-0.43 to 1.50) 
RV, z-score. -0.02 (-2.81 to 4.49) 1.10 (-1.59 to 6.24) 2.24 (1.38 to 3.22) -0.95 (-1.08 to -0.19) -1.50 (-2.98 to 1.67) -2.45 (-4.20 to -1.35) -0.79 (-2.34 to 0.16) -0.99 (-2.42 to 3.14) 
DLCO, z-score -0.84 (-1.96 to 1.25) -2.77 (-4.39 to -0.54) -1.89 (-3.98 to -0.67) -2.08 (-2.30 to -1.74) -2.44 (-4.77 to -1.98) -2.91 (-4.30 to -0.06) -2.80 (-4.17 to -2.33) -0.67 (-2.37 to -0.29) 
KCO, z-score 0.09 (-0.93 to 1.48) -2.05 (-2.93 to -0.27) -0.17 (-1.94 to 1.95) 0.53 (0.48 to 0.55) 0.18 (-1.86 to 1.73) -1.09 (-2.04 to 1.27) -2.02 (-3.53 to -1.17) -0.32 (-1.34 to -0.07) 
Definition of abbreviations: FEV1 = forced expiratory volume in one second; F = Female; FVC = forced vital capacity; DLCO = diffusing 
capacity for carbon monoxide; KCO = transfer coefficient for carbon monoxide; M= Male; TLC = total lung capacity; NMD = neuromuscular 
disease; ILD = interstitial lung diseases; PVD = pulmonary vascular diseases; OBD = other obstructive diseases; TD = Thoracic deformity/ 




Table 2: Confusion matrix with counts of all correctly and incorrectly labelled subjects per PFT pattern 
  Pulmonologist Pattern   










 Obstructive 1636 196 180 112 2124 18 
Restrictive 34 883 14 249 1180 10 
Normal 285 424 1872 15 2596 22 
Mixed 0 0 0 0 0 0 
 Total 1955 1503 2066 376 5900      
 Avg. N Sub.  17 13 17 3  50 
 Specificity 92% 87% 94% .   
 Sensitivity 77% 75% 72% .   
 PPV 84% 59% 91% .   
 NPV 88% 93% 81% .   
Rows show true reference PFT patterns, while columns show patterns labelled by pulmonologists. There are 4391 (=74.4%) correctly given 
interpretations (true positive in bold.). PPV, positive predictive value; NPV, negative predictive value; Avg. N Sub., averaged N subjects for 






Table 3: Confusion matrix with counts of all correctly and incorrectly labelled subjects per each diagnostic category 
  Pulmonologist Diagnosis   











Asthma 189 82 141 23 49 4 5 395 72 960 8 
COPD 157 859 154 4 6 28 49 22 41 1320 11 
OBD 77 139 162 13 15 5 6 45 18 480 4 
NMD 1 2 7 90 156 70 3 4 27 360 3 
TD 10 103 56 68 152 133 7 15 56 600 5 
ILD 2 9 5 58 168 533 167 205 53 1200 10 
PVD 2 55 27 8 18 75 266 11 18 480 4 
Healthy 21 24 10 6 9 7 49 426 48 600 5 
Other 0 0 0 0 0 0 0 0 0 0 0 
 Total 459 1273 562 270 573 855 552 1123 333 6000     
 Avg. N Sub. 3.8 10.6 4.7 2.3 4.8 7.1 4.6 9.4 2.8  50 
 Specificity 90% 81% 86% 93% 86% 87% 89% 76% .   
 Sensitivity 20% 65% 34% 25% 25% 44% 55% 71% 0%   
 PPV 41% 67% 29% 33% 27% 62% 48% 38% 0%   
 NPV 76% 80% 89% 91% 85% 76% 92% 93% .   
Rows show true reference diagnostic category, while columns show diagnosis labelled by pulmonologists. There are 2667 (=44.6%) correctly 
suggested diagnosis (true positive in bold.). PPV, positive predictive value; NPV, negative predictive value; Avg. N Sub., averaged N subjects 




Table 4: Confusion matrix with counts of all correctly and incorrectly labelled subjects by AI software per each diagnostic category 
  AI software Diagnosis  











Asthma 6 1 0 0 0 0 0 1 0 8 
COPD 0 11 0 0 0 0 0 0 0 11 
OBD 1 2 1 0 0 0 0 0 0 4 
NMD 0 0 0 3 0 0 0 0 0 3 
TD 0 0 0 2 3 0 0 0 0 5 
ILD 0 0 0 0 0 9 0 1 0 10 
PVD 0 1 0 0 0 0 3 0 0 4 
Healthy 0 0 0 0 0 0 0 5 0 5 
Other 0 0 0 0 0 0 0 0 0 0 
 Total 7 15 1 5 3 9 3 7 0 50 
 Specificity 97% 88% 100% 95% 100% 100% 100% 95% .  
 Sensitivity 75% 100% 25% 100% 60% 90% 75% 100% .  
 PPV 86% 73% 100% 60% 100% 100% 100% 71% .  
 NPV 95% 100% 93% 100% 95% 97% 97% 100% .  
 
Rows show true reference diagnostic category, while columns show diagnosis labelled by AI software. There are 41 (=82%) correctly suggested 





Artificial intelligence outperforms pulmonologists in the interpretation of 
pulmonary function tests  
Figure S1a: Example of a first page of the patient file with clinical information, complete pulmonary function 




















Figure S3: Report generated using in-house developed software. Probabilities for each diagnostic category 




Figure S4: Comparison of diagnostic accuracy per disease averaged for all individual pulmonologists. A/ 
Sensitivity (=True positive / (True positive + False Negative) shows how many relevant subjects (from specific 
group) were correctly identified. B/ Positive predictive value (=True positive / (True positive + False Positive) 
shows how many labelled subjects rightly belonged to the specific group. COPD = Chronic Obstructive 
Pulmonary Disease, ILD = Interstitial Lung Disease, NMD = Neuromuscular Disease, OBD = Other Obstructive 










Figure S6: Comparison of Likert scores when decision was correct (median (IQR)= 4 (3-4)) versus when 
decision was not correct (=3 (3-4)). 
 
 
